Endonovo said April 25 that NAMSA’s services are designed to increase payer retention. The collaboration is expected to allow Endonovo to explore reimbursement in both the U.S. and European medical markets.
“NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” Endonovo CEO Alan Collier said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.